Natural and synthetic agents targeting inflammation and angiogenesis for chemoprevention of prostate cancer

Current Cancer Drug Targets

Volumn 8, Issue 2, 2008, Pages 146-155

  Araldi, Elena M V ^a   Dell'Aica, Isabella ^c   Sogno, Ilaria ^a   Lorusso, Girieca ^a,b   Garbisa, Spiridione ^c   Albini, Adriana ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Cancer; Chemoprevention; Prostate

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; BETA CAROTENE; CAPSAICIN; CAROTENOID; CURCUMIN; DAIDZEIN; DUTASTERIDE; EPIGALLOCATECHIN GALLATE; FINASTERIDE; FLAVONOID; GENISTEIN; HYPERFORIN; LYCOPENE; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SABAL EXTRACT; SELENIUM; SILIBININ; STEROID 5ALPHA REDUCTASE INHIBITOR; THIOL DERIVATIVE; VITAMIN D;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DRUG TARGETING; HUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; SABAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION MEDIATORS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 40449125508     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908783769382     Document Type: Review

References (107)

1. Cunha, G. R.; Donjacour, A. A.; Cooke, P. S.; Mee, S.; Bigsby, R. M.; Higgins, S. J.; Sugimura, Y. The endocrinology and developmental biology of the prostate. Endocr. Rev. 1987, 8(3), 338-362.
2. Bonkhoff, H.; Remberger, K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996, 28(2), 98-106.
3. Hudson, D. L.; Guy, T.; Fry, P.; O'Hare, M. J.; Watt, F. M.; Masters, J. R. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J. Histochem. Cytochem. 2001, 49(2), 271-278.
4. Brawer, M. K.; Peehl, D. M.; Stamey, T. A.; Bostwick, D. G. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985, 45(8), 3663-3667.
5. Nagle, R. B.; Ahmann, F. R.; McDaniel, K. M.; Paquin, M. L.; Clark, V. A.; Celniker, A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987, 47(1), 281-286.
6. Verhagen, A. P.; Aalders, T. W.; Ramaekers, F. C.; Debruyne, F. M.; Schalken, J. A. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988, 13(1), 25-38.
7. Sherwood, E. R.; Berg, L. A.; Mitchell, N. J.; McNeal, J. E.; Kozlowski, J. M.; Lee, C. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J. Urol. 1990, 143(1), 167-171.
8. Konishi, N.; Nakamura, M.; Ishida, E.; Shimada, K.; Mitsui, E.; Yoshikawa, R.; Yamamoto, H.; Tsujikawa, K. High expression of a new marker PCA-1 in human prostate carcinoma. Clin. Cancer Res. 2005, 11(14), 5090-5097.
9. Theyer, G.; Kramer, G.; Assmann, I.; Sherwood, E.; Preinfalk, W.; Marberger, M.; Zechner, O.; Steiner, G. E. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab. Invest. 1992, 66(1), 96-107.
10. Steiner, G.; Gessl, A.; Kramer, G.; Schöllhammer, A.; Förster, O.; Marberger, M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J. Urol. 1994, 151(2): 480-484.
11. Kramer, G.; Marberger, M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr. Opin. Urol. 2006, 16(1), 25-29.
12. Lucia, M. S., Torkko, K. C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. 2004, 171(2 Pt 2), S30-S34.
13. Kim, R.; Emi, M.; Matsuura, K.; Tanabe, K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther. 2007, 14(1), 1-11.
14. Ho, E.; Boileau, T. W.; Bray, T. M. Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Arch. Biochem. Biophys. 2004, 428(1), 109-117.
15. Noonan, D. M.; De Lerma Barbaro, A.; Vannini, N.; Mortara, L.; Albini, A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008, 27(1), 31-40.
16. Charlesworth, P. J., Harris, A. L. Mechanisms of disease: angiogenesis in urologic malignancies. Nat. Clin. Pract. Urol. 2006, 3(3), 157-169.
17. De Marzo, A. M.; Platz, E. A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C. G.; Nakai, Y.; Isaacs, W. B.; Nelson, W. G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 2007, 7(4), 256-269.
18. Kelloff, G. J.; Crowell, J. A.; Steele, V. E.; Lubet, R. A.; Malone, W. A.; Boone, C. W.; Kopelovich, L.; Hawk, E. T.; Lieberman, R.; Lawrence, J. A.; Ali, I.; Viner, J. L.; Sigman, C. C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 2000, 130(2S Suppl.), 467S-471S.
19. Sporn, M. B.; Suh, N. Chemoprevention of cancer. Carcinogenesis 2000, 21(3), 525-530.
20. Tosetti, F.; Ferrari, N.; De Flora, S.; Albini, A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16(1), 2-14.
21. Huss, W. J.; Hanrahan, C. F.; Barrios, R. J.; Simons, J. W.; Greenberg, N. M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001, 61(6), 2736-2743.
22. Jiang, C.; Agarwal, R. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silybinin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem. Biophys. Res. Commun. 2000, 276(1), 371-378.
23. Bhatia, N.; Agarwal, C.; Agarwal, R. Differential responses of skin cancer-chemopreventive agents silybinin, quercetin, and epigallocatechin 3-gallate on mitogenic signalling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr. Cancer 2001, 39(2), 292-299.
24. Nelson, E. C.; Evans, C. P.; Mack, P. C.; Devere-White, R. W.; Lara, P. N. Jr. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prastatic Dis. 2007, 10(4), 331-339.
25. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D. P.; Dennison, A. R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 2006, 12(9), 2944-2950.
26. Raina, K.; Blouin, M. J.; Singh, R. P.; Majeed, N.; Deep, G.; Varghese, L.; Glodé, L. M.; Greenberg, N. M.; Hwang, D.; Cohen, P.; Pollak, M. N.; Agarwal, R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2007, 67(22), 11083-11091.
27. Lu, J.; Papp, L. V.; Fang, J.; Rodriguez-Nieto, S.; Zhivotovsky, B.; Holmgren, A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 2006, 66(8), 4410-4418.
28. Xing, N.; Chen, Y.; Mitchell, S. H.; Young, C. Y. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 2001, 22(3), 409-414.
29. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov. 2006, 5(6), 493-506.
30. Lee, K. W.; Lee, H. J. The roles of polyphenols in cancer chemoprevention. Biofactors 2006, 26(2), 105-121.
31. Benitez, D. A.; Pozo-Guisado, E.; Clementi, M.; Castellón, E.; Fernande-Salguero, P. M. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br. J. Cancer 2007, 96(10), 1595-1604.
32. Kundu, J. K.; Shin, Y. K.; Surh, Y.-J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-κB and AP-1 as prime targets. Biochem. Pharmacol. 2006, 72, 1506-1515.
33. Kundu, J. K.; Shin, Y. K.; Kim, S. H.; Surh, Y.-J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IkB kinase activity Carcinogenesis 2006, 27, 1465-1474.
34. Gill, C.; Walsh, S. E.; Morrissey, C.; Fitzpatrick, J. M.; Watson, R. W. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007, 67(15), 1641-1653.
35. Garbisa, S.; Biggin, S.; Cavallarin, N.; Sartor, L.; Benelli R.; Albini, A. Tumor invasion: molecular shears blunted by green tea. Nat. Med. 1999, 5, 1216.
36. Donà, M.; Dell'Aica, I.; Calabrese, F.; Benelli, R.; Morini, M.; Albini, A.; Garbisa, S. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 2003, 170(8), 4335-4341.
37. Fassina, G.; Venè, R.; Morini, M.; Minghelli, S.; Benelli, R.; Noonan, D. M.; Albini, A. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer. Res. 2004, 10(14), 4865-4873.
38. Jung, Y. D.; Kim, M. S.; Shin, B. A.; Chay, K. O.; Ahn, B. W.; Liu, W.; Bucana, C. D.; Gallick, G. E.; Ellis, L. M. EGCG, a major component of green tea, inhibits tumor growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer 2001, 84(6), 844-850.
39. Strasly, M.; Cavallo, F.; Geuna, M.; Mitola, S.; Colombo, M. P.; Forni, G.; Bussolino, F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 2001, 166(6), 3890-3899.
40. Siddiqui, I. A.; Adhami, V. M.; Afaq, F.; Ahmad, N.; Mukhtar, H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J. Cell Biochem. 2004, 91(2), 232-242.
41. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66(2), 1234-1240.
42. Syed, D. N.; Khan, N.; Afaq, F.; Mukhtar, H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 2007, 16(11), 2193-2203.
43. Adhami, V. M.; Malik, A.; Zaman, N.; Sarfaraz, S.; Siddiqui, I. A.; Syed, D. N.; Afaq, F.; Pasha, F. S.; Saleem, M.; Mukhtar, H. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 2007, 13(5), 1611-1619.
44. Maheshwari, R. K.; Singh, A. K.; Gaddipati, J.; Srimal, R. C. Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78(18), 2081-2087.
45. Holder, G. M.; Plummer, J. L.; Ryan, A. J. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978, 8(12), 761-768.
46. Pan, M. H.; Huang, T. M. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug. Metab. Dispos. 1999, 27(4), 486-494.
47. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnology 2007, 5(3), web pages not available.
48. Motterlini, R.; Foresti, R.; Bassi, R.; Green, C. J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic. Biol. Med. 2000, 28(8), 1303-1312.
49. Tegeder, I.; Niederberger, E.; Israr, E.; Gühring, H.; Brune, K.; Euchenhofer, C.; Grösch, S.; Geisslinger, G. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J. 2001, 15(3), 595-597.
50. Zhang, L.; Fiala, M.; Cashman, J.; Sayre, J.; Espinosa, A.; Mahanian, M.; Zaghi, J.; Badmaev, V.; Graves, M. C.; Bernard, G.; Rosenthal, M. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J. Alzheimer Dis. 2006, 10(1), 1-7.
51. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438(7070), 932-936.
52. Thaloor, D.; Singh, A. K.; Sidhu, G. S.; Prasad, P. V.; Kleinman, H. K.; Maheshwari, R. K. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Diff. 1998, 9(4), 305-312.
53. Bachmeier, B.; Nerlich, A. G.; Iancu, C. M.; Cilli, M.; Schleicher, E.; Vene, R.; Dell'Eva, R.; Jochum, M.; Albini, A.; Pfeffer, U. The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol. Biochem. 2007, 19(1-4), 137-152.
54. Duvoix, A.; Blasius, R.; Delhalle, S.; Schnekenburger, M.; Morceau, F.; Henry, E.; Dicato, M.; Diederich, M. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223(2), 181-190.
55. Martarelli, D.; Martarelli, B.; Pediconi, D.; Nabissi, M. I.; Perfumi, M.; Pompei, P. Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice. Cancer Lett. 2004, 210(1), 27-33.
56. Mueller, B. M. St. John's Wort for depressive disorders: results of an outpatient study with the Hypericum preparation HYP 811. Adv. Ther. 1998, 15(2), 109-116.
57. Singer, A.; Wonnemann, M.; Muller, W. E. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther. 1999, 290(3), 1363-1368.
58. Abrahamsson, P. A. Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer 1999, 6(4), 503-519
59. Grobholz, R.; Bohrer, M. H.; Siegsmund, M.; Junemann, K. P.; Bleyl, U.; Woenckhaus, M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol. Res. Pract. 2000, 196(5), 277-284.
60. Donà, M.; Dell'Aica, I.; Pezzato, E.; Sartor, L.; Calabrese, F.; Della Barbera, M.; Donella-Deana, A.; Appendino, G.; Borsarini, A.; Caniato, R.; Garbisa, S. Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 2004, 64, 6225-6232.
61. Dell'Aica, I.; Niero, R.; Piazza, F.; Cabrelle, A.; Sartor, L.; Colalto, C.; Brunetta, E.; Lorusso, G.; Benelli, R.; Albini, A.; Calabrese, F.; Agostini, C.; Garbisa, S. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J. Pharmacol. Exper. Ther. 2007, 321, 492-500.
62. Cabrelle, A.; Dell'Aica, I.; Melchiori, L.; Carraro, S.; Brunetta, E.; Niero, R.; Scquizzato, E.; D'Intino, G.; Calzà, L.; Garbisa, S.; Agostini, C. Hyperforin down-regulates effector function of activated T lymphocytes, and shows efficacy against Th1-triggered CNS inflammatory- demyelinating disease. J. Leukoc. Biol. 2008, 83(1), 212-219.
63. Spiegel, W.; Zidek, T.; Vutuc, C.; Maier, M.; Isak, K.; Micksche, M. Complementary therapies in cancer patients: prevalence and patients' motives. Wien Klin. Wochenschr. 2003, 115(19-20), 705-709.
64. Lowe, J. F.; Frazee, L. A. Update on prostate cancer chemoprevention. Pharmacotherapy 2006, 26(3), 353-359.
65. Hennekens, C. H.; Buring, J. E.; Manson, J. E.; Stampfer, M.; Rosner, B.; Cook, N. R.; Belanger, C.; LaMotte, F.; Gaziano, J. M.; Ridker, P. M.; Willett, W.; Peto, R. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasm and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1145-1149.
66. Liu, A; Pajkovic, N.; Pang, Y.; Zhu, D.; Calamini, B.; Mesecar, A. L.; van Breemen, R. B. Absorption and subcellular localization of lycopene in human prostate cancer cells. Mol. Cancer Ther. 2006, 5(11), 2879-2885.
67. Djavan, B.; Zlotta, A.; Schulman, C.; Teillac, P.; Iversen, P.; Boccon Gibod, L.; Bartsch, G.; Marberger, M. Chemotherapeutic prevention studies of prostate cancer. J. Urol. 2004, 171(2 Pt 2), S10-S13.
68. Peters, U.; Leitzmann, M. F.; Chatterjee, N.; Wang, Y.; Albanes, D.; Gelmann, E. P.; Friesen, M. D.; Riboli, E.; Hayes, R. B. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 2007, 16(5), 962-968.
69. Cook, N. R.; Stampfer, M. J.; Ma, J.; Manson, J. E.; Sacks, F. M.; Buring, J. E.; Hennekens, C. H. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer. 1999, 86(9), 1783-1792.
70. Kristal, A. R. Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. J. Urol. 2004, 171(2 Pt 2), S54-S58.
71. Yang, Y.; Ikezoe, T.; Zheng, Z.; Taguchi, H.; Koeffler, H. P.; Zhu, W. G. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int. J. Oncol. 2007, 31(3), 593-600.
72. Wadsworth, T. L.; Worstell, T. R.; Greenberg, N. M.; Roselli, C. E. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP). Prostate 2007, 67(6), 661-673.
73. Bent, S.; Kane, C.; Shinohara, K.; Neuhaus, J.; Hudes, E. S.; Goldberg, H.; Avins, A. L. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 2006, 354(6), 557-566.
74. Ames, B. N.; Wakimoto, P. Are vitamin and mineral deficiencies a major cancer risk? Nat. Rev. Cancer 2002, 2(9), 694-704.
75. Schwartz, G. G.; Hulka, B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990, 10(5A), 1307-1311.
76. Gross, M. D. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J. Nutr. 2005, 135(2), 326-331.
77. Skowronski, R. J.; Peehl, D. M.; Feldman, D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995, 136(1), 20-26.
78. Peehl, D. M.; Skowronski, R. J.; Leung, G. K.; Wong, S. T.; Stamey, T. A.; Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994, 54(3), 805-810.
79. Blutt, S. E.; McDonnell, T. J.; Polek, T. C.; Weigel, N. L. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000, 141(1), 10-17.
80. Cordell, G. A.; Araujo, O. E. Capsaicin: identification, nomenclature, and pharmacotherapy. Ann. Pharmacother. 1993, 27, 330-336.
81. Sindrup, S. H.; Jensen, T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83(3), 389-400.
82. Park, J. Y.; Kawada, T.; Han, I. S.; Kim, B. S.; Goto, T.; Takahashi, N.; Fushiki, T.; Kurata ,T.; Yu, R. Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism. FEBS Lett. 2004, 572(1-3), 266-270.
83. Min, J. K.; Han, K. Y.; Kim, E. C.; Kim, Y. M.; Lee, S. W.; Kim, O. H.; Kim, K. W.; Gho, Y. S.; Kwon, Y. G. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 2004, 64(2), 644-651.
84. Tuoya, B. N.; Shimoishi, Y.; Murata, Y.; Tada, M.; Koseki, M.; Takahata, K. Apoptosis induction by dohevanil, a DHA substitutive analog of capsaicin, in MCF-7 cells. Life Sci. 2006, 78, 515-519.
85. Jung, M. Y.; Kang, H. J.; Moon, A. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Cancer Lett. 2001, 165, 139-145.
86. Qiao, S.; Li, W.; Tsubouchi, R.; Haneda, M.; Murakami, K.; Yoshino, M. Involvement of peroxynitrite in capsaicin-induced apoptosis of C6 glioma cells. Neurosci Res. 2005, 51, 175-183.
87. Tsou, M. F.; Lu, H. F.; Chen, S. C.; Wu, L. T.; Chen, Y. S.; Kuo, H. M.; Lin, S. S.; Chung, J. G. Involvement of Bax, Bcl-2, Ca2+ and caspase-3 in capsaicin-induced apoptosis of human leukemia HL-60 cells. Anticancer Res. 2006, 26, 1965-1971.
88. Wu, C. C.; Lin, J. P.; Yang, J. S.; Chou, S. T.; Chen, S. C.; Lin, Y. T.; Lin, H. L.; Chung, J. G. Capsaicin induced cell cycle arrest and apoptosis in human esophagus epidermoid carcinoma CE 81T/VGH cells through the elevation of intracellular reactive oxygen species and Ca2+ productions and caspase-3 activation. Mutat. Res. 2006, 601, 71-82.
89. Bhutani, M.; Pathak, A. K.; Nair, A. S.; Kunnumakkara, A. B.; Guha, S.; Sethi, G.; Aggarwal, B. B. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin. Cancer Res. 2007, 13(10), 3024-3032.
90. Mori, A.; Lehmann, S.; O'Kelly, J.; Kumagai, T.; Desmond, J. C.; Pervan, M.; McBride, W. H.; Kizaki, M.; Koeffler, H. P. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res. 2006, 66(6), 3222-3229.
91. Sanchez, A. M.; Sanchez, M. G.; Malagarie-Cazenave, S.; Olea, N.; Diaz-Laviada, I. Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 2006, 11(1), 89-99.
92. Sanchez, A. M.; Malagarie-Cazenave, S.; Olea, N.; Vara, D.; Chiloeches, A.; Diaz-Laviada, I. Apoptosis induced by capsaicin in prostate PC-3 cells involves ceramide accumulation, neutral sphingomyelinase, and JNK activation. Apoptosis On line 2007 Sep 8.
93. Lippman, S.; Goodman, P. J.; Klein, E. A.; Parnes, H. L.; Thompson, I. M. Jr.; Kristal, A. R.; Santella, R. M.; Probstfield, J. L.; Moinpour, C. M.; Albanes, D.; Taylor, P. R.; Minasian, L. M.; Hoque, A.; Thomas, S. M.; Crowley, J. J.; Gaziano, J. M.; Stanford, J. L.; Cook, E. D.; Fleshner, N. E.; Lieber, M. M.; Walther, P. J.; Khuri, F. R.; Karp, D. D.; Schwartz, G. G.; Ford, L. G.; Coltman, C. A. Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Natl. Cancer Inst. 2005, 97(2), 94-102.
94. Duffield-Lillico, A. J.; Dalkin, B. L.; Reid, M. E.; Turnbull, B. W.; Slate, E. H.; Jacobs, E. T.; Marshall, J. R.; Clark, L. C. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003, 91(7), 608-612.
95. Li, H.; Stampfer, M. J.; Giovannucci, E. L.; Morris, J. S.; Willett, W. C.; Gaziano, J. M.; Ma, J. A prospective study of plasma selenium levels and prostate cancer risk. J. Natl. Cancer Inst. 2004, 96(9), 696-703.
96. Albini, A.; Noonan, M. D.; Ferrari, N. Molecular pathways for cancer angioprevention. Clin. Cancer Res. 2007, 13(15Pt1), 4320-4325.
97. Thompson, I. M.; Basler, J.; Hensley, D.; von Merveldt, D.; Jenkins, C. A.; Higgins, B.; Leach, R.; Troyer, D.; Pollock, B. Prostate cancer prevention: what do we know now and when will we know more? Clin. Prostate Cancer 2003, 1(4), 215-220.
98. Lucia, M. S.; Epstein, J. I.; Goodman, P. J.; Darke, A. K.; Reuter, V. E.; Civantos, F.; Tangen, C. M.; Parnes, H. L.; Lippman, S. M.; La Rosa, F. G.; Kattan, M. W.; Crawford, E. D.; Ford, L. G.; Coltman, C. A. Jr.; Thompson, I. M. F. Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2007, 99(18), 1375-1383.
99. Thompson, I. M.; Chi, C.; Ankerst, D. P.; Goodman, P. J.; Tangen, C. M.; Lippman, S. M.; Lucia, M. S.; Parnes, H. L.; Coltman, C. A. Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl. Cancer Inst. 2006, 98(16), 1128-1133.
100. Thompson, I. M.; Ankerst, P. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J. Clin. Oncol. 2007, 25(21), 3076-3081.
101. Isaacs, J. T.; Isaacs, W. B. Androgen receptor outwits prostate cancer drugs. Nat. Med. 2004, 10(1), 26-27.
102. Marihart, S.; Harik, M. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev. Urol. 2005, 7(4), 203-210.
103. Gomella, L. G. Chemoprevention using dutasteride: the REDUCE trial. Curr. Opin. Urol. 2005, 15(1), 29-32.
104. Klein, E. A.; Thompson, I. M. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis. 2000, 3(3), 145-151.
105. Blot, W. J.; Taylor, P. R. The Linxian trials: mortality rates by vitamin-mineral intervention group. Am. J. Clin. Nutr. 1993, 62(6 Suppl.), 1424S-1426S.
106. Venkateswaran, V.; Fleshner, N. E.; Klotz, L. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2004, 7(1), 54-56.
107. Surh Y. J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3(10), 768-780.